Dr. Moroz received his MD from the Academy of Medicine in Bialystok, Poland. He completed his anatomic pathology training at the Mallory Institute of Pathology, Boston University School of Medicine in Boston, followed by clinical pathology training at the University Hospital at Boston University School of Medicine. Dr. Moroz completed fellowship training in cytopathology at the Mallory Institute of Pathology at Boston University School of Medicine in 1994. He is board-certified in anatomic and clinical pathology (1993) and cytopathology (1994) by the American Board of Pathology. He is a fellow of the College of American Pathologists. Dr. Moroz joined Tulane University School of Medicine in 1994. He is actively participating in the cytopathology and surgical pathology services of the department. His research interests include breast and prostate cancer, and prognostic tumor markers. He is co-directing the Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium.
Biospecimen Core Laboratory is responsible for collection of quality and diversity of biologic specimens that meet national biobanking criteria. BCL is following standard operating procedures for all aspects of operation including but not limited to sample collection, processing, annotation, storage, distribution, quality control and assurance. Collected specimens are used for research at participating LCRC institutions.
Education: Academy of Medicine, Poland, Medical Doctor
Boston University School of Medicine – Residency in Pathology, Fellowship in Cytopathology
Publications:
Toraih EA, Ruiz E, Ning B, Tortelote GG, Hilliard S, Moroz K, Hu T, Fawzy MS, Kandil E. Chromatin-Accessible miRNA Regulons Driving Thyroid Tumorigenesis and Progression. J Am Coll Surg.2023 Jan 11. doi: 10.1097/XCS.0000000000000541. Online ahead of print. PMID:36728308
Toraih EA, Fawzy MS, Ning B, Zerfaoui M, ErramiY, Ruiz EM, Hussein MH, Haidari M, Bratton M, Tortelote GG, Hilliard S, NilubolN, Russell JO, Shama MA, El-Dahr SS, Moroz K, Hu T, Kandil E. AmiRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. Cancers(Basel). 2022 Aug 26;14(17):4128. doi: 10.3390/cancers14174128. PMID: 36077665
Hartono AB, Kang HJ, Shi L, Phipps W, Ungerleider N, Giardina A, Chen W, Spraggon L, Somwar R, Moroz K, DrewryDH, Burow ME, Flemington E, Ladanyi M, Lee SB. Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor. Oncogenesis.2022 Apr 20;11(1):18. doi: 10.1038/s41389-022-00395-6. PMID: 35443736
Aydin Y, Koksal AR, Thevenot P, Chava S,Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S .Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. J Hepatocell Carcinoma. 2021Dec 8;8:1579-1596. doi: 10.2147/JHC.S327339. eCollection 2021. PMID: 34917553
Toraih EA, Fawzy MS, Hussein MH, El-Labban MM, Ruiz EML, Attia AA, Halat S, Moroz K, Errami Y, Zerfaoui M, Kandil E. MicroRNA-Based Risk Score for Predicting Tumor Progression Following Radioactive Iodine Ablation in Well-Differentiated Thyroid Cancer Patients: A Propensity-Score Matched Analysis. Cancers (Basel). 2021 Sep 16;13(18):4649. doi:10.3390/cancers13184649. PMID: 34572876
Key words: biobanking, cancer, prognostic markers, pathology
